TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15066065

Group type: EXPERIMENTAL
Intervention: MK-0677
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 11495047

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg d(-1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg d(-1)
Number of subjects: 16
Study: 9763323

Group type: EXPERIMENTAL
Intervention: BOMP (probing marginal gingiva)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: BOPP (probing to the bottom of the pocket)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: BOMP
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: BOPP
Number of subjects: 25

Group type: COMPARATOR
Intervention: BOMP and BOPP
Number of subjects: 25
Study: 7824425

Group type: EXPERIMENTAL
Intervention: Capsaicin cream 0.025% applied twice daily
Number of subjects: 1
Study: 2901565

Group type: EXPERIMENTAL
Intervention: Naloxone (30 micrograms/kg intravenous bolus followed by 30 micrograms/kg/h infusion)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (equivalent volume bolus and infusion)
Number of subjects: 14
Study: 31694759

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 31856908

Group type: EXPERIMENTAL
Intervention: Variable-frequency stimulation (VFS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Constant-frequency stimulation
Number of subjects: 0
Study: 28008691

Group type: EXPERIMENTAL
Intervention: FAP therapist training (FAPTT) course, eight weekly sessions
Number of subjects: 25

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 25
Study: 26228365

Group type: EXPERIMENTAL
Intervention: Sequential therapy (Esomeprazole 20 mg bid for 10 days, amoxicillin 1000 mg for 5 days, then clarithromycin 500 mg and tinidazole 500 mg; both bid for 5 days)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Standard triple therapy (Esomeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1000 mg each bid for 14 days)
Number of subjects: 232
Study: 23754238

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX), n = 99
Number of subjects: 197

Group type: COMPARATOR
Intervention: Cyclophosphamide followed by Azathioprine (CYC/AZA), n = 98
Number of subjects: 197
Study: 20966901

Group type: EXPERIMENTAL
Intervention: Solid protein meal (steamed chicken breast + 750 ml water)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Liquefied protein meal (steamed chicken breast blended in 500 ml water + 250 ml water)
Number of subjects: 10
Study: 22009776

Group type: EXPERIMENTAL
Intervention: NovaBone grafting at fracture site
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (without NovaBone grafting)
Number of subjects: 78
Study: 17721754

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 46

Group type: COMPARATOR
Intervention: metformin
Number of subjects: 46

Group type: COMPARATOR
Intervention: control group
Number of subjects: 46
Study: 15216404

Group type: EXPERIMENTAL
Intervention: 1% brinzolamide ophthalmic solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 50
Study: 12470761

Group type: EXPERIMENTAL
Intervention: 16-Gy proton irradiation delivered in two fractions 24 hours apart
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham control treatment
Number of subjects: 37
Study: 10680493

Group type: EXPERIMENTAL
Intervention: rHGH (0.3u.Kg‐1 subcutaneously at 8 am each morning for 10 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 16
Study: 7609294

Group type: EXPERIMENTAL
Intervention: Clonidine 2.5 micrograms.kg‐1 orally
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral diazepam 0.1 mg.kg‐1 90 min prior to arrival in the operating room (Control)
Number of subjects: 20
Study: 2229458

Group type: EXPERIMENTAL
Intervention: Flurazepam 45 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 636912

Group type: EXPERIMENTAL
Intervention: Creatine kinase (CK) and lactate dehydrogenase isoenzymes analyzed with a column chromatographic method.
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Creatine kinase isoenzyme specificity for myocardial damage.
Number of subjects: 201
Study: 30358572

Group type: EXPERIMENTAL
Intervention: Right-side position (RRP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dorsal position (DRP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined position
Number of subjects: 90

Group type: COMPARATOR
Intervention: All groups (RRP, DRP, Combined)
Number of subjects: 90
Study: 29251975

Group type: EXPERIMENTAL
Intervention: Standard Treatment plus Contingency Management (STCM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard Treatment Alone (STA)
Number of subjects: 65
Study: 26064990

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Atorvastatin (both doses)
Number of subjects: 51
Study: 23479911

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 100
Study: 22224344

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Injectables
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Intra-uterine device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (non-contraceptive users)
Number of subjects: 100
Study: 19328267

Group type: EXPERIMENTAL
Intervention: Juice containing 50 mg DHA daily for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Juice containing 100 mg DHA daily for 6 weeks
Number of subjects: 0
Study: 16939483

Group type: EXPERIMENTAL
Intervention: Topical lidocaine (10 ml of 4% lidocaine)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 44
Study: 15312157

Group type: EXPERIMENTAL
Intervention: Oral administration of 8 mg of 14C‐labelled TCC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of TCC and M1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral administration of TCC vs. intramuscular administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of muscle relaxant activity of M1 and M2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bioanalytical method for TCC and M1
Number of subjects: 0
Study: 11745909

Group type: EXPERIMENTAL
Intervention: Andolast 2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Andolast 4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Andolast 8 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Andolast (all doses)
Number of subjects: 12
Study: 9290300

Group type: EXPERIMENTAL
Intervention: Long-term passive heat exposure during military training
Number of subjects: 30
Study: 8329700

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 441

Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (primary therapy)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Busulfan (primary therapy)
Number of subjects: 441
Study: 3546618

Group type: EXPERIMENTAL
Intervention: Maintenance BCG therapy (six-weekly doses of BCG plus monthly BCG for 2 years)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Nonmaintenance BCG therapy (BCG weekly for 6 weeks)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Maintenance BCG therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Nonmaintenance BCG therapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both groups (Maintenance and Nonmaintenance BCG therapy)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Absence of tumor after induction BCG
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Reactive tuberculin skin test before and after induction BCG
Number of subjects: 93
Study: 31455090

Group type: EXPERIMENTAL
Intervention: MCH‐ART integrated service
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard of care (immediate postpartum referral to separate services)
Number of subjects: 21
Study: 30630796

Group type: EXPERIMENTAL
Intervention: Combination of surgery, antibiotics, and wuwei xiaodu drink
Number of subjects: 80

Group type: COMPARATOR
Intervention: Surgery and antibiotics
Number of subjects: 80
Study: 26907482

Group type: EXPERIMENTAL
Intervention: Oral PPI (30 mg lansoprazole twice a day)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Intravenous PPI (120 mg pantoprazole)
Number of subjects: 166
Study: 25315828

Group type: EXPERIMENTAL
Intervention: CDP-choline 1000 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CDP-choline 500 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 23140964

Group type: EXPERIMENTAL
Intervention: Edwards Magna bioprosthesis
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Sorin Mitroflow bioprosthesis
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: St. Jude Epic bioprosthesis
Number of subjects: 300
Study: 20488328

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mononuclear cell (BM-MNC) infusion
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 17940145

Group type: EXPERIMENTAL
Intervention: Double-bundle with bioabsorbable screw fixation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Single-bundle with bioabsorbable screw fixation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Single-bundle with metallic screw fixation
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 77
Study: 15197206

Group type: EXPERIMENTAL
Intervention: Liver function tests (LFTs) including alkaline phosphatase, AST, ALT, or bilirubin
Number of subjects: 2320

Group type: EXPERIMENTAL
Intervention: Liver function tests (LFTs)
Number of subjects: 2320
Study: 11496617

Group type: EXPERIMENTAL
Intervention: 50 mg dolasetron given orally 45 minutes prior to induction of anaesthesia (group I)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 12.5 mg dolasetron given intravenously during induction of anaesthesia (group II)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 1.25 mg DHB given intravenously during induction of anaesthesia (group III)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo (group IV)
Number of subjects: 136
Study: 9725117

Group type: EXPERIMENTAL
Intervention: Mecamylamine (2.5‐5.0 mg twice per day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nicotine + mecamylamine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mecamylamine
Number of subjects: 80
Study: 8050424

Group type: EXPERIMENTAL
Intervention: Inspiratory limb capnography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimum inspired carbon dioxide at the mouth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fresh gas flow:minute volume ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expiratory limb capnography
Number of subjects: 0
Study: 2731601

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g daily for one week)
Number of subjects: 14
Study: 765079

Group type: EXPERIMENTAL
Intervention: Incision, curettage and primary suture under systemic antibiotic cover
Number of subjects: 219

Group type: COMPARATOR
Intervention: Deroofing and packing
Number of subjects: 219
Study: 30926190

Group type: EXPERIMENTAL
Intervention: F(ab)2 antivenom
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28627310

Group type: EXPERIMENTAL
Intervention: Cluster-level dynamic treatment regimens
Number of subjects: 0
Study: 25296928

Group type: EXPERIMENTAL
Intervention: Osmotic-Release Oral System Methylphenidate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24072224

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Glittre test (GT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) scores
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Quadriceps and biceps strength
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dyspnea scores
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GT performance
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GT and 6MWT correlation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GT and physical functioning domain of SF-36 correlation
Number of subjects: 45
Study: 21147422

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle exercise combined with routine treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Routine treatment including electrotherapy and general exercises
Number of subjects: 20
Study: 18348023

Group type: EXPERIMENTAL
Intervention: Synthetic colloids (4% succinylated gelatine or 6% pentastarch)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Blood transfusions
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Crystalloids
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (not receiving synthetic colloids)
Number of subjects: 160
Study: 16844888

Group type: EXPERIMENTAL
Intervention: 1-day training session for general practitioners (GPs) on managing patients with unexplained physical symptoms
Number of subjects: 295

Group type: COMPARATOR
Intervention: Untrained GPs
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 1-day training session for general practitioners (GPs)
Number of subjects: 295
Study: 12626993

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study: 11771602

Group type: EXPERIMENTAL
Intervention: Chlorhexidine impregnated dressing (Biopatch)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no dressing)
Number of subjects: 55
Study: 9419398

Group type: EXPERIMENTAL
Intervention: Dietary iron intake (averaged from self‐administered food frequency questionnaires, energy‐adjusted, categorized into quartiles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron supplements (limited examination)
Number of subjects: 0
Study: 8306007

Group type: COMPARATOR
Intervention: Intensive glycemic control
Number of subjects: 529

Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 529
Study: 2949672

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 17
Study: 29510490

Group type: EXPERIMENTAL
Intervention: BIOLIGOTM IL5040 isomaltooligosaccharide
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BIOLIGOTM IL7010 isomaltooligosaccharide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dextrose (control)
Number of subjects: 36
Study: 26846471

Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg daily, 5 mg three times a day)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no meloxicam)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Meloxicam (15 mg daily, 5 mg three times a day) in patients without viral hepatitis (NBNC-HCC)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control group (no meloxicam) in patients without viral hepatitis (NBNC-HCC)
Number of subjects: 224
Study: 24952837

Group type: EXPERIMENTAL
Intervention: Treadmill training (30 minutes, three times a week for four months)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study: 23488651

Group type: EXPERIMENTAL
Intervention: Soy isolate protein (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soy isolate protein + resistance exercises (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 60
Study: 20857256

Group type: EXPERIMENTAL
Intervention: Videolaryngoscope (VL group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL group)
Number of subjects: 68
Study: 18178947

Group type: EXPERIMENTAL
Intervention: Bicarbonate/lactate-based (Bic/Lac) solution
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional lactate-based (Lac) solution
Number of subjects: 26
Study: 16189338

Group type: EXPERIMENTAL
Intervention: Low-dose intrathecal morphine (6 microg x kg(‐1) per ideal body weight in 5 mL normal saline)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Low-dose intrathecal morphine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intrathecal normal saline (5 mL)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intrathecal normal saline
Number of subjects: 43
Study: 12499341

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (500 or 1000 mg/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10532104

Group type: EXPERIMENTAL
Intervention: Ondansetron (syrup) plus dexamethasone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron plus dexamethasone (per os)
Number of subjects: 52
Study: 8546549

Group type: EXPERIMENTAL
Intervention: Monetary incentive ($5 payment)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Peer health adviser (assistance by a peer)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Usual care (referral slips and bus tokens only)
Number of subjects: 244
Study: 2062873

Group type: COMPARATOR
Intervention: Scopolamine (0.6 mg p.o.)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Powdered ginger (500 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Powder ginger (500 or 1,000 mg) or fresh ginger root (1,000 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: Gastric emptying
Number of subjects: 28
Study: 3900809

Group type: EXPERIMENTAL
Intervention: Shoulder exercises started immediately after surgery (Group A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Shoulder exercises started on the seventh postoperative day (Group B)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 57
Study: 30219102

Group type: EXPERIMENTAL
Intervention: Physiotherapy plus wrist orthosis (PT + O)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Physiotherapy (PT)
Number of subjects: 61
Study: 27093770

Group type: EXPERIMENTAL
Intervention: 2.7 mL of 2% mepivacaine with 1:100,000 epinephrine and 1 mL of 75 TRU/mL hyaluronidase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (1 mL of saline)
Number of subjects: 0
Study: 24286636

Group type: EXPERIMENTAL
Intervention: Fasudil (2.67 mmol/L)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Papaverine (1.0 mmol/L)
Number of subjects: 45

Group type: COMPARATOR
Intervention: VG (30 μmol/L each of verapamil and nitroglycerin)
Number of subjects: 45
Study: 22510505

Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel plus cisplatin (LP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paclitaxel plus cisplatin (TP)
Number of subjects: 100
Study: 19626043

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 15

Group type: COMPARATOR
Intervention: Usual diet supplemented with potassium, magnesium and fibre
Number of subjects: 15
Study: 18782643

Group type: EXPERIMENTAL
Intervention: Eating disorder symptoms in patients with bipolar disorder
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Loss of control over eating (LOC)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Weekly LOC during the past six months
Number of subjects: 81
Study: 17219172

Group type: EXPERIMENTAL
Intervention: Hyperoxic air (1.0 O(2)) during exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normoxic air (0.21 O(2)) during exercise
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Resting metabolites with oxygen supplementation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Resting metabolites without oxygen supplementation
Number of subjects: 6
Study: 16083172

Group type: EXPERIMENTAL
Intervention: Partial Body Weight Support Treadmill Training (PBWSTT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Floor walking training (Control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (PBWSTT and Floor walking training)
Number of subjects: 48
Study: 15700491

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg or 8 mg once daily
Number of subjects: 678

Group type: COMPARATOR
Intervention: Doxazosin standard 1 mg to 8 mg once daily
Number of subjects: 678
Study: 9142604

Group type: EXPERIMENTAL
Intervention: Norplant implantable contraceptives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Licensing in industrialized countries
Number of subjects: 0
Study: 8416463

Group type: EXPERIMENTAL
Intervention: Home management
Number of subjects: 67

Group type: COMPARATOR
Intervention: Hospital management
Number of subjects: 67
Study: 3743441

Group type: EXPERIMENTAL
Intervention: Isophane human insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isophane pork insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protamine-bound biosynthetic human insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Porcine preparations
Number of subjects: 0
Study: 31439338

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (OAC)
Number of subjects: 1621

Group type: EXPERIMENTAL
Intervention: OAC with antiplatelet therapy (APT)
Number of subjects: 1621

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (APT) alone
Number of subjects: 1621

Group type: COMPARATOR
Intervention: No OAC or APT
Number of subjects: 1621
Study: 28634906

Group type: EXPERIMENTAL
Intervention: bCBT
Number of subjects: 302

Group type: COMPARATOR
Intervention: EUC
Number of subjects: 302
Study: 25773757

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 24 weeks
Number of subjects: 155
Study: 23892201

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5599

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5599
Study: 21631670

Group type: EXPERIMENTAL
Intervention: Standard trabeculectomy (4 × 4 mm scleral flap)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Microtrabeculectomy (2 × 2 mm scleral flap)
Number of subjects: 41
Study: 19321589

Group type: EXPERIMENTAL
Intervention: High-phytate meal
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Enzymatic dephytinization
Number of subjects: 34

Group type: COMPARATOR
Intervention: Fermentation of maize porridge
Number of subjects: 34
Study: 16440160

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) administered at 20 ng/kg per minute
Number of subjects: 0